More questions than answers as Moderna's coronavirus vaccine speeds ahead

Moderna's announcement Monday that its experimental coronavirus vaccine spurred potentially meaningful immune responses in eight patients was good enough news to lift global markets and enable the Massachusetts-based biotech to raise more than $1 billion from investors.